Clinical trialPhase 1Active not recruiting
M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Phase I Clinical Trial of M6620 (VX-970, Berzosertib) in Combination With the Topoisomerase I Inhibitor Irinotecan in Patients With Advanced Solid Tumors
- Outcome
- Ongoing
- Phase
- Phase 1
- Status
- Active not recruiting
- Study type
- Interventional
- Start
- 22 July 2016
- Expected end
- 6 March 2027
- Enrollment
- 66 participants
- Sites
- 23
- Primary outcomes
- Maximum tolerated dose (MTD); Recommended phase 2 dose (RP2D) of ATR kinase inhibitor M6620 (VX-970, berzosertib) and irinotecan hydrochloride
- Sponsor type
- NIH
- Results posted
- No
- Last update
- 18 November 2026
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This phase I trial studies the side effects and best dose of M6620 and irinotecan hydrochloride in treating patients with solid tumors that have spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). M6620 and irinotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Detailed description public domain (ClinicalTrials.gov)
PRIMARY OBJECTIVE: I. To determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of M6620 (VX-970, berzosertib) in combination with irinotecan hydrochloride (irinotecan) in patients with advanced solid tumors. SECONDARY OBJECTIVES: I. To estimate the safety and tolerability of M6620 (VX-970, berzosertib) in combination with irinotecan. II. To document anti-tumor activity. III. To determine the pharmacokinetic (PK) and pharmacodynamic (PD) parameters of M6620 (VX-970, berzosertib) and irinotecan. EXPLORATORY OBJECTIVE: I. To identify molecular subpopulations of patients with increased sensitivity to the irinotecan and M6620 (VX-970, berzosertib) combination. OUTLINE: This is a dose-escalation study. Patients receive irinotecan hydrochloride intravenously (IV) over 90 minutes and M6620 IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo biopsy and collection of blood samples throughout the study and undergo CT at screening, throughout the study, and during follow up. After completion of study treatment, patients are followed up for 30 days, then at 3 and 6 months.
Intervention public domain (ClinicalTrials.gov)
Drug: Berzosertib. Given IV
Intervention public domain (ClinicalTrials.gov)
Procedure: Biopsy Specimen. Undergo biopsy
Intervention public domain (ClinicalTrials.gov)
Procedure: Biospecimen Collection. Correlative studies
Intervention public domain (ClinicalTrials.gov)
Procedure: Computed Tomography. Undergo CT
Intervention public domain (ClinicalTrials.gov)
Drug: Irinotecan Hydrochloride. Given IV
Arm public domain (ClinicalTrials.gov)
Treatment (irinotecan, M6620) (experimental): Patients receive irinotecan hydrochloride IV over 90 minutes and M6620 IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo biopsy and collection of blood samples throughout the study and undergo CT at screening, throughout the study, and during follow up.
Primary outcome public domain (ClinicalTrials.gov)
Maximum tolerated dose (MTD). Will be defined as the highest dose level at which =\< 20% patients experience dose limiting toxicity. A logistic regression model will be used to determine the MTD using all patients. Time frame: Up to 28 days.
Primary outcome public domain (ClinicalTrials.gov)
Recommended phase 2 dose (RP2D) of ATR kinase inhibitor M6620 (VX-970, berzosertib) and irinotecan hydrochloride. The RP2D will be determined based on MTD and the feasibility of the administration. Time frame: Up to 28 days.
Secondary outcome public domain (ClinicalTrials.gov)
Incidence of adverse events of M6620 (VX-970, berzosertib) and irinotecan hydrochloride. Time frame: Up to 6 months after completion of study treatment.
Secondary outcome public domain (ClinicalTrials.gov)
Overall response rate. Time frame: Up to 6 months after completion of study treatment.
Secondary outcome public domain (ClinicalTrials.gov)
Incidence of stable disease. Time frame: Up to 6 months after completion of study treatment.
Secondary outcome public domain (ClinicalTrials.gov)
Progression-free survival. Time frame: Duration of time from start of treatment to time of progression or death, whichever occurs first, assessed up 6 months after completion of study treatment.
Secondary outcome public domain (ClinicalTrials.gov)
Pharmacokinetic parameters of M6620 (VX-970, berzosertib) in combination with irinotecan hydrochloride. Time frame: Days -14 through -11, 1, 2, and 15 through 18 of cycle 1 (each cycle = 28 days).
Secondary outcome public domain (ClinicalTrials.gov)
Pharmacodynamic parameters of M6620 (VX-970, berzosertib) in combination with irinotecan hydrochloride. Time frame: Up to day 15 of cycle 1 (each cycle = 28 days).
Eligibility public domain (ClinicalTrials.gov)
Inclusion Criteria: * Patients must have histologically confirmed metastatic or unresectable malignancy that is refractory to standard therapy or for which no standard therapy exists and where irinotecan is deemed a reasonable treatment option * FOR PATIENTS ENROLLED IN THE EXPANSION COHORT: Patients must have known deficiencies in the deoxyribonucleic acid (DNA)-Damage Response (DDR), e.g. mutations in ATM, PALB2, BRCA1/2 or other deficiencies after discussion with the Study Chair (prioritized), or patients can be enrolled with the following tumor types regardless of known DDR deficiency: pancreatic cancer, colorectal cancer, and small cell lung cancer * Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as \>= 20 mm (\>= 2 cm) with conventional techniques or as \>= 10 mm (\>= 1 cm) with spiral CT scan, magnetic resonance imaging (MRI), or calipers by clinical exam * No limit on prior lines of therapy for metastatic disease; prior adjuvant or neoadjuvant chemotherapy does not count as a prior line of therapy as long as completion of the adjuvant or neoadjuvant therapy was more than 1 year prior to patient enrollment * Age \>= 18 years. Because no dosing or adverse event data are currently available on the use of M6620 (VX-970, berzosertib) in combination with irinotecan in patients \< 18 years of age, children are excluded from this study, but will be eligible for future pediatric trials * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 (Karnofsky \>= 70%) * Life expectancy of greater than 12 weeks * Leukocytes \>= 3,000/mcL * Absolute neutrophil count \>= 1,500/mcL * Platelets \>= 100,000/mcL * Total bilirubin within normal institutional limits * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 2.5 x institutional upper limit of normal (ULN); if liver involvement, =\< 5 x ULN * Creatinine clearance \>= 60 mL/min/1.73 m\^2 * Patients must have archived tumor tissue from prior tumor biopsy or surgical resections available for submission that is sufficient to complete molecular profiling * FOR PATIENTS ENROLLED IN THE EXPANSION COHORT: Willingness to undergo mandatory biopsies (day -13, approximately 18 to 22 hours post end of irinotecan infusion and day 2, …
Enrollment public domain (ClinicalTrials.gov)
Enrollment: 66 participants (actual).